Castle Biosciences, Inc. revised earnings guidance for the full year of 2024. The company is increasing its guidance for anticipated total revenue in 2024. The company now anticipates generating between $255 million to $265 million in total revenue in 2024, compared to the previously provided guidance of between $235 million to $240 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.16 USD | -2.89% | -4.97% | +2.69% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.69% | 612M | |
-10.64% | 11.61B | |
-11.02% | 7.65B | |
+30.85% | 5.62B | |
-16.28% | 3.85B | |
+8.39% | 2.62B | |
-64.67% | 2.37B | |
-10.53% | 2.24B | |
+24.87% | 2.16B | |
-12.06% | 1.76B |
- Stock Market
- Equities
- CSTL Stock
- News Castle Biosciences, Inc.
- Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024